(1) Publication number:

0 166 937

@

EUROPEAN PATENT APPLICATION

(2) Application number: 85106209.1

2 Date of filing: 21.05.85

(9) Int. Ct. C 07 D 233/22

C 07 D 239/06, C 07 D 239/26 C 07 C 123/00, A 61 K 31/415

A 61 K 31/505, C 07 D 405/04

30 Priority: 06.06.84 US 617770

 Date of publication of application: 08.01.85 Bulletin 86/2

(B) Designated Contracting States: BE CH DE FR GB IT IJ NIL SE ② Applicant: ABBOTT LABORATORIES 14th Street and Sheridan Road North St North Chicago (Minols 60064(US)

(7) inventor: DeBernandia, John Francis 35 Burnett Avenue Lake Villa, IL 60046(US)

(2) Inventor: Basha, Fatima Zehra 232 Bayshore Drive Lake Bluff, IL 60044(US)

(*) Representative: Modlano, Guido et al. MODIANO, JOSIF, PISANTY & STAUB Modiano & Associati Via Meravigli, 16 1-20123 Milan(IT)

Adrenergic compounds.

(5) Disclosed herein are adrenergic compounds represented. by the formula

wherein n is 1 or 2, and the dashed line represents a single or double bond when n is 1, and Re is taken from the group consisting of hydrogen, loweralityl, or anytalityl, and the pharmaceutically acceptable salts thereof.

wherein m is 0, 1 or 2; R_{3r} R_{3r} R₃ are taken from the group consisting of hydrogen, hydroxy, loweralkyt, loweralkoxy, halo, or NHSO₂R wherein R is taken from the group consisting of hydrogen, loweralltyl or anylalityl, provided that R₁, R₂, R₃ cannot simultaneously be hydrogen, and provided that when one of Rt, Rp, Rs is helo, the other two cannot simultaneously be hydrogen; R_1 and R_2 or R_2 and R_3 taken together can form a methylenedioxy or ethylenedioxy bridge; and Re and Re are hydrogen or taken together form a closed ring of the formula